Dr. Ryan F. Porter, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Wisconsin (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 483
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Medical College of Wisconsin
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WI license 62133-20
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ssm Health St Mary's Hospital - Madison Madison, WI
- Fort Memorial Hospital Fort Atkinson, WI
- Ssm Health St Mary's Hospital - Janesville Janesville, WI
- Stoughton Hospital Stoughton, WI
- Columbus Community Hospital Columbus, WI
Medical groups
- Dean Health Systems Inc (1,159 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 483
- Services billed
- 106,748
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg | 1,697 | 46 |
| Injection, palonosetron hcl, 25 mcg | 850 | 23 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 622 | 75 |
| Insertion of needle into vein for collection of blood sample | 539 | 189 |
| Established patient office or other outpatient visit, 30-39 minutes | 475 | 203 |
| Injection, fluorouracil, 500 mg | 435 | 14 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 334 | 116 |
| Injection of additional new drug or substance into vein | 323 | 55 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 305 | 14 |
| Administration of chemotherapy into vein, 1 hour or less | 255 | 68 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 413 |
| Prednisone Other prescribers in Madison, WI | 376 |
| Potassium Chloride Other prescribers in Madison, WI | 101 |
| Ondansetron Hcl Other prescribers in Madison, WI | 77 |
| Eliquis (apixaban) Other prescribers in Madison, WI | 75 |
| Prochlorperazine Maleate Other prescribers in Madison, WI | 65 |
| Anastrozole Other prescribers in Madison, WI | 64 |
| Bicalutamide | 63 |
| Oxycodone Hcl Other prescribers in Madison, WI | 59 |
| Erleada (apalutamide) | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $115 in total to this clinician.
| Tempus Ai, Inc | $115 |
|---|
| Food and Beverage | $115 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $9,555 in research payments for these studies, mostly to the institutions running them.
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo Inc. · Recruiting · NCT07129993
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.